Andrew Matthews

7PUBLICATIONS
19CO-AUTHORS
Gene and molecular therapyMedical biotechnology diagnostics (incl. biosensors)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy era.

Xin Wang, Phyllis A Gimotty, Andrew H Matthews

|Mar 27, 2024
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.

Andrew Matthews, Elena Fenu, Sarah J Skuli

|Mar 20, 2024
<i>RAD21</i> mutations in acute myeloid leukemia.

Dorottya Laczko, Corey Poveda-Rogers, Andrew H Matthews

|Feb 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.

Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy

|Jun 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.

Andrew H Matthews, Alexander E Perl, Selina M Luger

|Dec 11, 2022
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia.

Andrew H Matthews, Keith W Pratz, Martin P Carroll

Pageof 2

Frequent Collaborators

3 joint publications

Alexander E Perl

2 joint publications

Ivan P Maillard

2 joint publications

Noelle V Frey

2 joint publications

Elizabeth O Hexner